Lipirose-AS 20 Capsule is a combination medication containing Rosuvastatin 20 mg and Aspirin 75 mg, formulated for the management of cardiovascular risk factors. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby reducing the risk of atherosclerotic cardiovascular disease. Aspirin, an antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), leading to decreased thromboxane A2 production and subsequent inhibition of platelet aggregation, which helps prevent thrombotic events such as myocardial infarction and stroke. Lipirose-AS 20 Capsule is indicated for patients requiring both lipid-lowering therapy and antiplatelet prophylaxis, particularly those with established coronary artery disease, history of myocardial infarction, or at high risk for cardiovascular events. The combination improves patient compliance by reducing pill burden. It is essential to monitor liver function tests, lipid profile, and signs of bleeding during therapy. Use with caution in patients with active peptic ulcer disease, bleeding disorders, or hypersensitivity to aspirin or statins. Lipirose-AS 20 Capsule should be used under medical supervision, with lifestyle modifications including diet and exercise to optimize cardiovascular outcomes.